PSS33 - SECUKINUMAB AS FIRST BIOLOGIC TREATMENT- A COST PER RESPONDER ANALYSIS COMPARED WITH LICENSED BIOLOGICS, FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA
Abstract
Authors
P.M. Bianculli M. Salibe I. Peirano I. Gilloteau C. Graham